You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Frequently responsive myeloproliferative and lymphoproliferative disorders: Malignant lymphomas including Hodgkins (Stages III and IV, Peter's Staging System*) and non-Hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *Modified as the International Staging Classification for Hodgkin's Disease in 'Report of the Committee on the Staging of Hodgkin's Disease'. Cancer Res 26: 1310, 1966. Stage I. Disease limited to one anatomic region (Stage I) or two contiguous anatomic regions (Stage I2) on the same side of the diaphragm. Stage II. Disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. Stage III. Disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or Waldeyer's ring. Stage IV. Involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or Waldeyer's ring. All stages are subclassified as A or B to indicate the absence or presence, respectively, of systemic symptoms. Frequently responsive solid malignancies: Neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. Infrequently responsive malignancies: Carcinoma of the breast; malignant neoplasms of the lung. Immunosuppressive properties: Cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. Wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. Cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Frequently responsive myeloproliferative and lymphoproliferative disorders: Malignant lymphomas including Hodgkins (Stages III and IV, Peter's Staging System*) and non-Hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *Modified as the International Staging Classification for Hodgkin's Disease in 'Report of the Committee on the Staging of Hodgkin's Disease'. Cancer Res 26: 1310, 1966. Stage I. Disease limited to one anatomic region (Stage I) or two contiguous anatomic regions (Stage I2) on the same side of the diaphragm. Stage II. Disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. Stage III. Disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or Waldeyer's ring. Stage IV. Involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or Waldeyer's ring. All stages are subclassified as A or B to indicate the absence or presence, respectively, of systemic symptoms. Frequently responsive solid malignancies: Neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. Infrequently responsive malignancies: Carcinoma of the breast; malignant neoplasms of the lung. Immunosuppressive properties: Cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. Wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. Cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Frequently responsive myeloproliferative and lymphoproliferative disorders: Malignant lymphomas including Hodgkins (Stages III and IV, Peter's Staging System*) and non-Hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *Modified as the International Staging Classification for Hodgkin's Disease in 'Report of the Committee on the Staging of Hodgkin's Disease'. Cancer Res 26: 1310, 1966. Stage I. Disease limited to one anatomic region (Stage I) or two contiguous anatomic regions (Stage I2) on the same side of the diaphragm. Stage II. Disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. Stage III. Disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or Waldeyer's ring. Stage IV. Involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or Waldeyer's ring. All stages are subclassified as A or B to indicate the absence or presence, respectively, of systemic symptoms. Frequently responsive solid malignancies: Neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. Infrequently responsive malignancies: Carcinoma of the breast; malignant neoplasms of the lung. Immunosuppressive properties: Cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. Wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. Cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
